276 related articles for article (PubMed ID: 21963351)
1. Animal models of multiple system atrophy.
Fernagut PO; Tison F
Neuroscience; 2012 Jun; 211():77-82. PubMed ID: 21963351
[TBL] [Abstract][Full Text] [Related]
2. In vivo models of multiple system atrophy.
Fernagut PO; Ghorayeb I; Diguet E; Tison F
Mov Disord; 2005 Aug; 20 Suppl 12():S57-63. PubMed ID: 16092092
[TBL] [Abstract][Full Text] [Related]
3. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
Bassil F; Guerin PA; Dutheil N; Li Q; Klugmann M; Meissner WG; Bezard E; Fernagut PO
Mov Disord; 2017 Aug; 32(8):1230-1239. PubMed ID: 28556404
[TBL] [Abstract][Full Text] [Related]
4. Grading of neuropathology in multiple system atrophy: proposal for a novel scale.
Jellinger KA; Seppi K; Wenning GK
Mov Disord; 2005 Aug; 20 Suppl 12():S29-36. PubMed ID: 16092088
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism.
Park HJ; Bang G; Lee BR; Kim HO; Lee PH
Cell Transplant; 2011; 20(6):827-35. PubMed ID: 21054946
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein transgenic mice: relevance to multiple system atrophy.
Fillon G; Kahle PJ
Mov Disord; 2005 Aug; 20 Suppl 12():S64-6. PubMed ID: 16092093
[TBL] [Abstract][Full Text] [Related]
7. In vitro models of multiple system atrophy.
Stefanova N; Reindl M; Poewe W; Wenning GK
Mov Disord; 2005 Aug; 20 Suppl 12():S53-6. PubMed ID: 16092091
[TBL] [Abstract][Full Text] [Related]
8. Tau-positive glial cytoplasmic granules in multiple system atrophy.
Nagaishi M; Yokoo H; Nakazato Y
Neuropathology; 2011 Jun; 31(3):299-305. PubMed ID: 21062361
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of neuronal degeneration of multiple system atrophy].
Yoshida M; Sone M
Brain Nerve; 2009 Sep; 61(9):1051-60. PubMed ID: 19803404
[TBL] [Abstract][Full Text] [Related]
10. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies.
Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N
Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733
[TBL] [Abstract][Full Text] [Related]
11. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease.
Marmion DJ; Rutkowski AA; Chatterjee D; Hiller BM; Werner MH; Bezard E; Kirik D; McCown T; Gray SJ; Kordower JH
Neurobiol Dis; 2021 Jan; 148():105184. PubMed ID: 33221532
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Stefanova N; Poewe W; Wenning GK
Exp Neurol; 2008 Apr; 210(2):421-7. PubMed ID: 18222424
[TBL] [Abstract][Full Text] [Related]
13. Multiple system atrophy: alpha-synuclein and neuronal degeneration.
Yoshida M
Neuropathology; 2007 Oct; 27(5):484-93. PubMed ID: 18018485
[TBL] [Abstract][Full Text] [Related]
14. Role of transcriptional control in multiple system atrophy.
Chen J; Mills JD; Halliday GM; Janitz M
Neurobiol Aging; 2015 Jan; 36(1):394-400. PubMed ID: 25218777
[TBL] [Abstract][Full Text] [Related]
15. Models of multiple system atrophy.
Fellner L; Wenning GK; Stefanova N
Curr Top Behav Neurosci; 2015; 22():369-93. PubMed ID: 24338664
[TBL] [Abstract][Full Text] [Related]
16. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.
Bassil F; Fernagut PO; Bezard E; Pruvost A; Leste-Lasserre T; Hoang QQ; Ringe D; Petsko GA; Meissner WG
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9593-8. PubMed ID: 27482103
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model.
Stefanova N; Georgievska B; Eriksson H; Poewe W; Wenning GK
Neurotox Res; 2012 May; 21(4):393-404. PubMed ID: 22161470
[TBL] [Abstract][Full Text] [Related]
19. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
20. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
